Lakefront Biotherapeutics (LKFT) Gains from Equity Investments (2023 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Gains from Equity Investments for 3 consecutive years, with $12.6 million the latest figure, recorded in Q4 2025.

• Quarterly Gains from Equity Investments fell 82.66% year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $152.9 million (up 374.51% YoY) and the FY2025 annual result came in at -$44.8 million, down 141.13% from the prior year.
• Gains from Equity Investments grew to $12.6 million in Q4 2025 per LKFT's latest filing, from -$10.7 million in the prior quarter.
• Over the last five years, Gains from Equity Investments for LKFT reached as high as $78.2 million in Q3 2024 and fell as low as -$76.8 million in Q2 2024.
• A 3-year average of $5.3 million and a median of $284488.6 in 2023 frame the typical range for Gains from Equity Investments.
• The largest YoY upside for Gains from Equity Investments was 420.0% in 2024 against a maximum downside of 781.62% in 2024.
• Year by year, Gains from Equity Investments stood at -$22.8 million in 2023, then soared by 420.0% to $72.8 million in 2024, then slumped by 82.66% to $12.6 million in 2025.
• According to Business Quant data, Gains from Equity Investments over the past three periods registered $12.6 million, -$10.7 million, and $72.8 million for Q4 2025, Q1 2025, and Q4 2024 respectively.